Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aligos Therapeutics, Inc.

11.44
+1.1611.28%
Post-market: 11.450.0100+0.09%18:54 EDT
Volume:137.74K
Turnover:1.56M
Market Cap:69.95M
PE:-0.89
High:11.76
Open:10.75
Low:10.62
Close:10.28
Loading ...

BRIEF-Aligos Therapeutics Strengthens Senior Leadership Team With The Appointment Of Hardean Achneck, MD As Chief Medical Officer

Reuters
·
24 Sep 2024

Aligos Therapeutics Strengthens Senior Leadership Team With the Appointment of Hardean Achneck, Md as Chief Medical Officer

THOMSON REUTERS
·
24 Sep 2024

Press Release: Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

Dow Jones
·
24 Sep 2024

Piper Sandler Sticks to Their Buy Rating for Aligos Therapeutics (ALGS)

TIPRANKS
·
24 Sep 2024

Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease

GlobeNewswire
·
23 Sep 2024

Buy Recommendation: Aligos Therapeutics’ ALG-055009 Shows Promise in Phase 2a with Advancement and Partnership Potential

TIPRANKS
·
20 Sep 2024

Aligos' fatty liver disease treatment meets main goal in mid-stage study

Reuters
·
19 Sep 2024

Aligos Therapeutics Inc - Alg-055009 Well-Tolerated With No Serious Adverse Events

THOMSON REUTERS
·
19 Sep 2024

Aligos Therapeutics Inc - Alg-055009 Dose Groups Met Primary Endpoint With Statistically Significant Reductions in Liver Fat at Week 12

THOMSON REUTERS
·
19 Sep 2024

Aligos Therapeutics Announces Positive Topline Results From the Phase 2a Herald Study of Alg-055009 for the Treatment of Mash

THOMSON REUTERS
·
19 Sep 2024

Aligos Therapeutics - Plan to Complete Activities Required for Phase 2B Study by Middle of 2025

THOMSON REUTERS
·
19 Sep 2024

Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH

GlobeNewswire
·
19 Sep 2024

Aligos Therapeutics to Announce Topline Results From the Phase 2a Herald Study of Alg-055009 for the Treatment of Mash on September 19, 2024

THOMSON REUTERS
·
19 Sep 2024

Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024

GlobeNewswire
·
19 Sep 2024